Establishment Labs Holdings Inc. $ESTA Shares Sold by First Light Asset Management LLC

First Light Asset Management LLC cut its stake in Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 17.5% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 307,738 shares of the company’s stock after selling 65,344 shares during the period. Establishment Labs makes up approximately 1.6% of First Light Asset Management LLC’s investment portfolio, making the stock its 22nd biggest position. First Light Asset Management LLC’s holdings in Establishment Labs were worth $17,473,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Establishment Labs by 20.1% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 57,215 shares of the company’s stock worth $2,335,000 after purchasing an additional 9,557 shares during the period. Geode Capital Management LLC increased its position in shares of Establishment Labs by 1.2% during the 2nd quarter. Geode Capital Management LLC now owns 25,917 shares of the company’s stock valued at $1,105,000 after purchasing an additional 299 shares during the period. WINTON GROUP Ltd acquired a new position in shares of Establishment Labs during the 2nd quarter valued at $651,000. Nebula Research & Development LLC raised its stake in shares of Establishment Labs by 27.9% in the 2nd quarter. Nebula Research & Development LLC now owns 16,214 shares of the company’s stock worth $692,000 after buying an additional 3,538 shares in the last quarter. Finally, Sei Investments Co. raised its stake in shares of Establishment Labs by 13.3% in the 2nd quarter. Sei Investments Co. now owns 48,428 shares of the company’s stock worth $2,068,000 after buying an additional 5,668 shares in the last quarter. Institutional investors and hedge funds own 72.91% of the company’s stock.

Establishment Labs Price Performance

NASDAQ ESTA opened at $92.32 on Monday. The stock has a market capitalization of $2.72 billion, a P/E ratio of -61.96 and a beta of 1.06. Establishment Labs Holdings Inc. has a 1 year low of $33.35 and a 1 year high of $96.99. The business’s fifty day moving average is $82.58 and its two-hundred day moving average is $72.77. The company has a debt-to-equity ratio of 16.82, a quick ratio of 1.91 and a current ratio of 2.96.

Establishment Labs (NASDAQ:ESTA) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.10). The company had revenue of $59.88 million for the quarter, compared to the consensus estimate of $57.40 million. Establishment Labs had a negative return on equity of 218.77% and a negative net margin of 19.05%.The business’s revenue was up 44.7% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.70) earnings per share. On average, research analysts forecast that Establishment Labs Holdings Inc. will post -1.07 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently weighed in on ESTA. TD Cowen restated a “buy” rating on shares of Establishment Labs in a report on Monday, June 8th. Citigroup lifted their target price on Establishment Labs from $76.00 to $92.00 and gave the stock a “neutral” rating in a report on Wednesday, July 8th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Establishment Labs in a research report on Wednesday, June 24th. Mizuho upped their price target on shares of Establishment Labs from $100.00 to $105.00 and gave the company an “outperform” rating in a report on Wednesday, July 15th. Finally, BTIG Research restated a “buy” rating on shares of Establishment Labs in a research report on Monday, July 13th. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $90.43.

Insider Activity at Establishment Labs

In other news, Director Quiros Juan Jose Chacon sold 105,000 shares of the company’s stock in a transaction on Wednesday, May 6th. The stock was sold at an average price of $75.42, for a total transaction of $7,919,100.00. Following the completion of the sale, the director directly owned 927,504 shares of the company’s stock, valued at $69,952,351.68. This represents a 10.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders sold 180,000 shares of company stock worth $13,225,275 over the last three months. Corporate insiders own 9.99% of the company’s stock.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.